BioWorld Asia

April 20, 2005

Arakis, Vectura Enter Potential $375M Novartis Deal For AD 237

LONDON - Two UK companies with a jointly developed product signed one of the biggest deals to date in European biotechnology, agreeing to a potential $375 million license with Novartis AG for their treatment of chronic obstructive pulmonary disease (COPD). (BioWorld International) Read More

Investor Interest Wanes For Australia's Biotech Stocks

DNA-Repair Inhibitors Poised To Cut Swath In Breast Cancer

EU Imposes Panic Measures To Block Importing Of Bt10

French Parliamentary Committee In Favor Of Field Trials For GMOs

ReOx Gaining $9M Via Deal With Unnamed U.S. Biotech

DNage Spun Out To Develop Therapies For Aging Diseases

Can Tissera Revive Plunging Stock Under New Leadership?

Crucell Lands EUR21M NIH Contract To Produce Ebola Virus Vaccine

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 9, 2026.

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...